A sensitive enzyme-linked immunosorbent assay was used for the simultaneous assessment of the amount of von Willebrand factor (vWF) in canine plasma and its ability to bind to canine collagen in vitro. In 60 normal dogs, there was close correlation between the concentration of vWF and its activity as determined by vWF-collagen binding. In 14 dogs with type I expressions of von Willebrand's disease, the ratio of vWF antigen to collagen binding activity was normal or only slightly increased. In 7 dogs with type II expressions of the disease, this ratio was consistently elevated suggesting a significant functional deficiency of the protein.
Von Willebrand factor (vWF) is a large glycoprotein that plays a key role in hemostasis by facilitating the adhesion and aggregation of blood platelets at sites of vascular injury. This multimeric protein is synthesized by megakaryocytes and endothelial cells in a complex process ultimately involving the polymerization of a basic 230-270-kd subunit. 13 vWF is found in plasma, endothelial cells, and the subendothelium itself. Unlike human and feline platelets, however, canine platelets contain very little vWF. 22 In plasma, vWF exists as a family of multimers ranging in size from about 1 million to 20 million daltons. 12, 13 Larger multimers are present in the subendothelium and in the Weibel-Palade bodies of endothelial cells, where the protein is stored. The different sizes of vWF multimers can be separated and visualized by sodium dodecyl sulfate gel electrophoresis using a diagnostic procedure called multimeric analysis (MA). 21 The functional activity of vWF results from the presence along the protein of specific receptors or ligands. Collagen is probably one of the major subendothelial components with which vWF interacts during the platelet adhesion process. 17 At least 2 binding sites for collagen have been identified on the protein: one in the A1 repeat and one in the A3 repeat. 11, 23 The binding of vWF to subendothelial elements results in conformational changes to the protein that are essential for the interaction of vWF with platelet glycoprotein 1b (GP1b) receptors (integrin ␣ 2 ␤ 1 ). This GP1b-vWFsubendothelial interaction leads to platelet adhesion From the Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.
Received for publication May 4, 1998. and transduction of an intraplatelet signal that leads to expression of the GPIIb/IIIa receptors (integrin ␣ IIb ␤ 3 ) on the platelet membrane. The activated platelet GPIIb/IIIa complex can also bind vWF, enhancing platelet spreading and causing irreversible adhesion and aggregation of the platelets. The larger vWF multimers have the greatest functional activity. 5, 13, 17 Quantitative and/or qualitative deficiencies of vWF account for the group of congenital bleeding disorders collectively known as von Willebrand's disease (vWD). [19] [20] [21] Human vWD is classified into 3 major types (I-III); types I and II each have a variety of subtypes. The analysis of the multimeric structure of vWF in plasma and/or in platelets currently forms the basis for this classification. 6, [18] [19] [20] Type I vWD is characterized by a quantitative deficiency of vWF but with a full range of multimer sizes detectable by MA. Type II vWD is characterized by normal or reduced amounts of vWF protein but with a significant reduction or absence of the higher molecular weight multimers. Type III vWD, or severe vWD, is characterized by extremely low or undetectable levels of vWF and therefore few or no identifiable vWF multimers. A similar typing classification has been applied to canine vWD, the most common inherited bleeding disorder in the dog. 12, 14 Although concentrations of vWF protein can be easily and precisely quantitated, it is more difficult to reliably assess the functional activity of the protein. Ristocetin-induced and botrocetin-induced platelet aggregation have been used for the qualitative assessment of vWF; however, these assays are not particularly sensitive, and the ristocetin assay in particular has been difficult to use with canine plasma. 4, 8, 15, 16 MA has been used as an indirect predictor of the quality of vWF protein based on the observation that the larger plasma vWF multimers appear to be the most functional. However, this laboratory procedure is complex and time consuming to perform and is impractical for large volume screening. 9 A more recent development in techniques for the assessment of vWF quality has been the evaluation of the protein's ability to bind to collagen in vitro. 1, 24 vWF-collagen binding is very dependent on the presence of the more functionally active high molecular weight multimers and better reflect the probable in vivo activity of vWF. 2, 25 The purpose of the present study was to develop and characterize a vWF-collagen binding assay for dogs. A second objective was to compare vWF-collagen binding activity (vWF-CBA) in plasmas from normal dogs with that in plasmas from dogs diagnosed with type I, type II, and type III expressions of canine vWD.
Materials and methods
Selection of dogs. Sixty dogs considered to be free of vWD and 21 dogs with vWD were identified through a screening program for canine hemostatic disorders. Diagnosis of vWD was made on the basis of clinical and family history and laboratory testing. The laboratory identification and classification of canine vWD types was based on quantitation of plasma vWF antigen (Ag) and analysis of the multimeric composition of vWF as previously described. 9, 12, 14 Examples of typical multimeric profiles for plasmas from normal dogs and dogs classified with type I vWD, type II vWD, and type III vWD are shown in Fig. 1 Normally with this MA technique, at least 15 multimer bands (numbered from the anode) are visible in profiles of normal canine plasma. 9 The 14 type 1 dogs identified each had a subnormal plasma concentration of vWF Ag (Ͻ70% of normal) but had a normal spectrum of vWF multimers (bands 1-15ϩ identifiable on MA). This group consisted of 6 doberman pinschers, 2 golden retrievers, 2 Shetland sheepdogs (one represented in lane B, Fig. 1 ), 1 Welsh Pembroke corgi, 1 standard schnauzer, 1 Airedale terrier, and 1 Irish wolfhound. Five of the dogs had a clinical history of a significantly increased tendency to bleed (1 or more of the following symptoms: severe oral bleeding, epistaxis, ''shifting'' lameness, heavy estral bleeding, excessive postsurgical bleeding).
The 7 type II vWD dogs had normal or reduced amounts of plasma vWF protein but a complete absence of the higher molecular weight multimers (only bands 1-10 or less identifiable on MA). This group consisted of 2 German shepherds (lanes C and G, Fig. 1 ), 1 Shetland sheepdog, 1 Welsh Pembroke corgi, 1 miniature pinscher (lane F, Fig. 1 ), 1 rottweiler, and 1 mixed breed dog. Three of these dogs had a history of significant bleeding episodes (1 or more of the following symptoms: severe oral bleeding, heavy estral bleeding, excessive postsurgical bleeding).
The 3 type III vWD dogs were all Shetland sheepdogs. Each had Ͻ2% vWF Ag and 0 or 1 band identifiable on MA of plasma (similar to lane D, Fig. 1 ). All 3 dogs had a clinical history of severe bleeding episodes (epistaxis and/or excessive postsurgical bleeding).
Blood collection. Blood samples were drawn by clean venipuncture into chilled 3.8% trisodium citrate at a ratio of 1:9 anticoagulant : blood. The citrated blood was immediately centrifuged (2,500 ϫ g for 20 min) at 4 C, and the upper two-thirds of the plasma supernatant was harvested and held at Ϫ70 C until assayed.
The blood collection was performed in accordance with the guidelines set by the Canadian Council on Animal Care and was approved by a committee concerned with ethical review at the University of Guelph.
Quantitation of plasma vWF-CBA and vWF Ag. vWF-CBA was quantitated using an enzyme-linked immunosorbent assay (ELISA) technique to assess the ability of canine vWF to bind to canine collagen coated to a solid phase support. 1 Plasma vWF Ag concentrations were quantitated using a sandwich ELISA technique adapted for use with canine plasma. 10 This procedure assesses the ability of canine vWF to bind to anti-vWF antibody attached to a solid phase support. The laboratory protocol was designed so that both vWF-CBA and vWF Ag concentration in a canine plasma sample could be quantitated simultaneously on the same microtiter plate.
One-half of a 96-well polystyrene microtiter plate a was coated using 100-l volumes of 0.25% canine acid-soluble collagen diluted 1:12.5 in a 0.05 M carbonate b coating buffer, pH 9.6. The collagen solution was prepared as previously described, 3 except that fresh canine tendon was used as the collagen source. Preliminary experiments with a range of dilutions of this stock collagen indicated that a 1:12.5 dilution produced optical density readings in the desired range. The wells in the other half of the microtiter plate were coated using 100-l volumes of rabbit anti-human vWF antibody c diluted 1:1,000 in the same coating buffer.
After the addition of the appropriate coating solutions, the microtiter plate was covered and incubated overnight at 4 C in a humidity chamber. The plate was then drained of coating solution using a manual plate washer d and washed 3 times with a phosphate-buffered saline (PBS)/Tween e washing solution, pH 7.2. A 100-l volume of the appropriate plasma diluted in PBS/Tween buffer (or PBS/Tween alone for blanking) was added to each well. All samples were assayed in triplicate.
The plate was covered and incubated in a humidity chamber at 37 C for 1.5 hr. During the last 15 min of this incubation period, a 1:1,000 concentration of peroxidase-conjugated rabbit anti-human vWF second antibody f in PBS/ Tween buffer was prepared. At the end of the incubation period, the plate was washed 3 times in PBS/Tween washing buffer. After the final wash, all wells were completely drained and 100 l of conjugated antibody was quickly added to each well. The plate was covered and placed back in the 37 C humidity chamber for a further 60 min.
Shortly before the end of this second incubation period, a 4-mg tablet of O-phenylenediamine g (OPD) was dissolved in 12.5 ml of 0.1 M citric acid-phosphate b substrate buffer (pH 5.0) and placed in a dark location. At the completion of the incubation period, the plate was washed 3 times with PBS/Tween washing solution and given a final wash with the substrate buffer. The plate was drained, the OPD solution was activated by the addition of 3.5 l of 30% hydrogen peroxide, b and 100 l of the activated OPD was quickly added to each well. The plate was covered and placed at room temperature in a dark location. After 45 min, the reaction was stopped by the rapid addition of 100 l of 5 N sulfuric acid to each well. Five minutes later, the optical density of the wells was read at 490 nm using a microplate reader. d Normal canine reference plasma was prepared by pooling citrated plasmas from a minimum of 10 clinically normal adult mixed-breed dogs. The plasma was divided into aliquots and stored at Ϫ70 C. This plasma was arbitrarily designated as having 100% vWF Ag and 100% vWF-CBA.
The relationship between vWF Ag and vWF-CBA in normal canine plasmas was examined using Pearson's correlation analysis. Analysis of vWF Ag and vWF-CBA concentrations and vWF Ag : vWF-CBA ratios in the various groups of dogs was performed using an unpaired Student's t-test. The level for significance was set at P Ͻ 0.05.
Results
Dose-response curves. In preliminary studies, serial dilutions of canine reference plasma were used to compare the linear regions of the dose-response curves and the lower limits of sensitivity of the assays for the quantitation of vWF-CBA and vWF Ag concentration. Examples of typical dose-response curves are shown in Fig. 2 . Individual plasmas were assayed at 2 different dilutions in both assay systems to confirm doseresponse parallelism. Based on these studies, plasma dilutions of 1:40-1:1,280 were ultimately used to establish the reference curve for vWF-CBA quantitation in individual plasmas, and dilutions of 1:80-1:2,560 were used to produce the vWF Ag reference curve. Individual plasma samples were assayed in the vWF-CBA and vWF Ag assays in triplicate at 1:80 and 1: 160 dilutions, respectively. The sensitivity of the vWF-CBA and vWF Ag assays was determined to be 0.04% and 0.02%, respectively.
Precision of the vWF-CBA and vWF Ag assays. Between-assay variability in the vWF-CBA and vWF Ag assays was assessed by 6 determinations (in triplicate) over a 2-month period on 2 different plasmas (normal and low levels of vWF-CBA and vWF Ag). The coefficient of variation for interassay variability in the quantitation of vWF-CBA and vWF Ag was identical for both assays, ranging from 3.0% to 3.5%. The same batch of collagen was used throughout. Within-assay variability as assessed by 6 determinations (in triplicate) on each of 2 different plasmas was 4.5%-5.3% and 2.0%-2.3% for the vWF-CBA and vWF Ag assays, respectively. The relationship between vWF-CBA and vWF Ag in normal canine plasma. The binding of canine vWF to collagen (vWF-CBA) and to antibody (vWF Ag) was compared in plasma samples from 60 clinically normal adult dogs of various breed, including mixed-breed dogs. Plasma vWF-CBA in normal dogs ranged from 63.6% to 170.8% of the activity of the canine reference plasma, with a mean of 101.5% (Table 1) . Individual plasma vWF Ag concentrations ranging from 66.8% to 174.0% of that in the canine reference plasma, with a mean of 100.2%. There was a high degree of correlation (r ϭ 0.89) between vWF-CBA and vWF Ag concentration in individual normal canine plasmas.
When the relationship between vWF protein concentration and collagen binding activity was examined, the vWF Ag : vWF-CBA ratios in normal canine plasma ranged from 0.80 to 1.36, with a mean of 1.00.
Binding of vWF to collagen in dogs with type I vWD. In the 14 type I vWD dogs, vWF-CBA ranged from 7.1% to 40.6%, with a mean of 22.2%, significantly lower than that in the normal dogs (Table 1) . Plasma vWF Ag in the type I dogs ranged from 9.4% to 47.8%. As a group, the type I dogs had an average vWF Ag : vWF-CBA ratio slightly greater than that for normal dogs (P Ͻ 0.05). In 9 of these dogs, there was a close relationship between vWF-CBA and vWF Ag levels (vWF Ag : vWF-CBA ratios within the range seen in normal dogs). Two of the type I dogs had slightly elevated vWF Ag : vWF-CBA ratios (1.58-1.70), and 3 had more pronounced elevations (1.96-2.52). The 3 dogs with the highest ratios were those that had clinical histories suggestive of a moderately severe bleeding disorder.
Binding of vWF to collagen in dogs with type II vWD. In the 7 dogs identified with a type II expression of vWD, plasma vWF-CBA activity ranged from 3.3% to 16.0%, with a mean of only 9.0% (Table 1) . This value was significantly lower than that for the normal dogs or those with type I vWD. Plasma vWF Ag in the type II dogs ranged from 9.6% to 76.9%, with a mean value that was significantly lower than that of the normal dogs but was not significantly different from that of the type I dogs. The vWF Ag : vWF-CBA ratios in the type II dogs were consistently above the reference range and, as a group, significantly higher than those of the normal dog group or the type I vWD group. The 3 dogs with the positive history of excessive bleeding had ratios of 2.48, 5.44, and 7.19.
Binding of vWF to collagen in dogs with type III vWD. Plasma vWF-CBA in the 3 type III dogs ranged from 0.2% to 1.0% of normal, with a mean of 0.6% (Table 1) . Plasma vWF Ag ranged from 0% to 1.8% of normal, with a mean of 1.1%. The vWF Ag : vWF-CBA ratios in the 3 dogs studied were 1.00, 2.50, and 3.00.
Discussion
The method used in the present study to assess the functional activity of canine vWF is based on the ability of vWF to bind to collagen fibers in vitro. The assay system was designed so that quantitation of the protein could be determined concurrently.
The source of collagen is an important factor in collagen binding assays. Soluble preparations are better at producing a uniform coating surface than are suspension preparations. 1 In this study, a crude acid-soluble collagen preparation made from canine gastrocnemius tendon was used. To ensure uniform coating of the microtiter plate wells, however, it was necessary to ensure that the coating buffer was warmed to room temperature before preparing the collagen coating solution and that the collagen and buffer were mixed thoroughly by gentle repeated inversion of the plastic dilution tube.
The results of this study show that in dogs there is normally a close correlation between the plasma concentrations of vWF (vWF Ag) and the protein's functional ability as assessed by its collagen binding activity (vWF-CBA). In individual plasma samples, this relationship was expressed as a vWF Ag : vWF-CBA ratio, a ratio of 1.00 indicating perfect correlation between quantity and functional activity and an abnormally high discrepancy in this ratio suggested a dysfunctional vWF profile. 1, 23, 24 Type I vWD is generally considered to be a disorder in which the patient produces subnormal quantities of a normal vWF protein. 19, 20 In dogs in this study with type I vWD profiles, the average vWF Ag : vWF-CBA ratio was slightly above normal. This increase was attributable primarily to 3 of the dogs in this group who had ratios approximately 2-2.5 times normal. Although these dogs met the criteria for type I classification (reduced vWF Ag and 15ϩ multimer bands detectable on MA), the apparent functional defect suggested by the elevated ratios in these patients may have been the result of a relative reduction in the concentrations of the larger multimers. A reduction in the concentration of the more functional active vWF multimers concurrent with a quantitative reduction in the amount of protein could be a factor in explaining the apparent increased clinical bleeding tendency reported in 3 of these dogs. A distinction between human type IA and type IB vWD has been made based on the fact that in type IB vWD all multimers are present, but the larger ones, although detectable on MA, are reduced in concentration relative to the others. 9 The MA technique does not accurately quantitate the amount of each multimer.
The majority of the type I vWD dogs did however have normal vWF Ag : vWF-CBA ratios, suggesting that in these patients the deficiency in vWF was strictly quantitative. Only 2 of these dogs had plasma vWF Ag concentrations of Ͻ17%, which could explain why only 2 dogs had a history of significant spontaneous bleeding. Plasma concentrations of 15-30% predispose to a degree of subclinical hemostatic compromise that often requires added stresses to make it apparent, and spontaneous bleeding is rare. 7 The apparent heterogeneity within this group of type I dogs suggests that, as with human vWD, there are subtypes within the canine type I classification. These subtypes likely reflect different mutations in the vWF protein that result, in some cases, not only in a reduction in plasma vWF but also in the production of a protein that is somewhat dysfunctional and may partially explain some of the differences reported in the clinical expression of canine type I vWD. Dogs with type I vWD and comparable plasma vWF Ag concentrations can frequently differ significantly in the severity of their clinical bleeding tendency. 7, 12 Type II vWD primarily involves a qualitative defect in vWF, although there may also be a concurrent quantitative deficiency. 19, 20 Such a scenario might be expected to result in an elevated vWF Ag : vWF-CBA ratio if the vWF that is present does not react well with collagen. Each of the type II dogs in this study had an elevated ratio, suggesting a functional deficiency in the protein. This deficiency in vWF-CBA activity in canine plasmas totally lacking the larger vWF multimers supports the relationship between multimer size and functional activity of this hemostatic protein. As has been reported in human studies, the binding of canine vWF to collagen appears to be very dependent on the larger multimers. 2 Plasma vWF Ag : vWF-CBA ratios of Ͼ2.5 in humans are considered highly suggestive of type IIA or type IIB vWD. 4 All of the dogs in this study with type II vWD profiles had ratios Ͼ2.1.
The 3 type III vWD dogs identified in this study had extremely low concentrations of vWF and little or no evidence of vWF multimers. Therefore, as might be expected in a condition in which the deficiency can be attributed to suppressed synthesis of vWF protein, there was negligible vWF-CBA activity in the plasma. In such situations, the use of vWF Ag : vWF-CBA ratios is irrelevent because their calculation is imprecise (because of the minute amounts being quantitated), and the condition can be diagnosed with a quantitative assay alone.
In the present study, a laboratory diagnostic procedure that permits the simultaneous assessment of both the antigenic and functional activity of vWF in canine plasma samples was used. This procedure may be a satisfactory alternative to MA for the detection of type II variant forms of canine vWD, forms that cannot be reliably identified on the basis of quantitative vWF assays alone. Because of the overlap in the ratios in the type I and type II groups, the results of this study suggest that vWF Ag : vWF-CBA ratios of Ͼ2.40 should be considered as probable type II expressions of vWD. This ELISA is more sensitive and is easier to perform than other functional assays that have been used with canine plasma (ristocetin-or botrocetin-induced platelet aggregation). 8, 15, 16 It is much less costly, less time consuming, and less technically complex than MA, and it is more readily adaptable to rapid large-volume screening. 8 It may be a useful screening test for identifying variant forms of canine vWD, particularily when MA or molecular biology techniques are not readily available. Canine plasma vWF-collagen binding activity e. Bio-Rad Laboratories, Hercules, CA. f. P226, Dako A/S Produktionsvej, Glostrup, Denmark. g. Sigma Chemical Co., St. Louis, MO.
